Abstract: Envenomation by haemotoxic enzymes remains a significant source of human morbidity and mortality worldwide, with administration of long-acting or multiple doses of antivenom first-line therapy. However, coagulopathy can still occur and recur. Of interest, it has been recently demonstrated that direct, isolated exposure of snake venom enzymes with fibrinogenolytic activity to carbon monoxide (CO) abrogates venom-mediated loss of coagulation in human plasma. These observations of CO inhibition of venom fibrinogenolytic activity were subsequently repeated in rabbit whole blood. This study sought to translate these findings in an in vivo rabbit model of envenomation with fibrinogenolytic Crotalus atrox venom. Sedated rabbits were intravenously administered C. atrox venom (400 lg/kg) pre-exposed to 0 or 1000 lM carbon monoxide-releasing molecule-2 (CORM-2) in vitro. Arterial whole-blood samples demonstrated that compared to pre-envenomation values, the CORM-2-na€ ıve venom significantly prolonged the onset of coagulation, decreased the velocity of clot growth and decreased clot strength as determined by thromboelastography an hour after venom injection. In contrast, CORM-2 pre-exposure prevented or attenuated C. atrox venom effects on coagulation kinetics. Future studies to determine whether rabbits injected with such venom subcutaneously/intramuscularly can have consequent coagulopathy abrogated by injection of carbon monoxide-releasing molecules into the 'bite site' are justified.
Envenomation by haemotoxic enzymes remains a significant source of human morbidity and mortality worldwide [1] . The most effective treatment against coagulopathy in this setting still remains the administration of long-acting or multiple doses of antivenom as recently demonstrated [2] ; however, coagulopathy can still occur and recur. Of interest, as a therapy complementary to antivenom, our laboratory discovered that direct, isolated exposure of snake venom metalloproteinases (SVMP) and snake venom serine proteases (SVSP) to carbon monoxide (CO) in vitro resulted in a marked decrease in associated fibrinogenolytic or thrombin-like activity in human plasma [3] [4] [5] [6] . This observation was then extended into and confirmed in an in vitro whole-blood rabbit model wherein the SVMP fibrinogenolytic activity of Crotalus atrox venom was attenuated by pre-exposure to CO [7] . In sum, direct inhibition of SVMP/SVSP by CO was found in vitro to have potential to complement traditional antivenom administration when treating patients envenomed with fibrinogenolytic enzymes.
However, the next step in assessing potential utility of CO for inhibiting SVMP fibrinogenolytic activity was to develop a pre-clinical model of envenomation that could have coagulopathy induced and assessed over time. To this end, a novel, sedated New Zealand White (NZW) rabbit model of C. atrox venom administration and thromboelastographic assessment of coagulation was established [7] , with the time course of loss of whole-blood coagulation function following exposure to a few concentrations of venom determined. The rabbit was chosen for this investigation as this model provides thromboelastographic coagulation kinetic data very similar to that of human beings, with similar contributions to clot strength from platelets and plasma proteins as discerned by platelet inhibition with cytochalasin D [8, 9] . Further, the ultrastructure of human and rabbit plasma thrombi has remarkably similar ultrastructure as determined by scanning electron microscopy [10] . Thus, the purpose of the present investigation was to utilize this pre-clinical model to determine whether pre-treatment of C. atrox venom in vitro with CO would reduce the fibrinogenolytic coagulopathy this venom induces when injected in vivo as assessed by thromboelastography.
Materials and Methods
Rabbits. Sixteen, male, NZW rabbits (1.9-2.2 kg) were obtained from Charles River Laboratories (San Diego, CA, USA) and then maintained within our animal facilities and allowed food and water ad libitum for at least one week prior to experimentation. The Institutional Animal Care and Utilization Committee of the University of Arizona approved all procedures involving these rabbits (protocol #16-165).
C. atrox venom and chemicals. One hundred milligrams of lyophilized C. atrox venom was obtained from the National Natural Toxins Research Center at Texas A&M University, Kingsville, TX, USA (a generous gift from Elda E. S anchez). The venom was reconstituted in calcium-free phosphate-buffered saline (PBS, SigmaAldrich, Saint Louis, MO, USA) at a concentration of 50 mg/ml, aliquoted and stored at À80°C until experimentation. CORM-2 Thromboelastographic analyses. Specific volumes of subsequently described whole blood and chemical additives varied by condition but summated to 360 ll. Samples that had intact platelet function consisted of 350 ll of whole blood to which 10 ll of TF (0.1% final concentration, in distilled water) was added; the mixture was then mixed by moving the fluid in the cup up and down onto the pin thrice. Samples with platelet inhibition contained 340 ll of whole blood to which 10 ll of cytochalasin D (5 lM concentration) was added; this mixture was mixed the fluid in the cup up and down onto the pin thrice. This concentration of cytochalasin D reliably inhibits platelet activity in rabbit blood as assessed by thromboelastography [8] . Thirty seconds later, 10 ll of TF was added to the platelet-inhibited sample and mixed as before. Data collection commenced immediately after TF addition for all samples, with collection terminated after 30 min. All sample mixtures were in a disposable cup in a computer-controlled thrombelastographâ haemostasis system (Model 5000, Haemonetics Inc., Braintree, MA, USA) at 39°C, the normal temperature of the NZW rabbit [11] . The following elastic modulus-based parameters previously described [3] [4] [5] [6] [7] were determined: time to maximum rate of thrombus generation (TMRTG): this is the time interval (minutes) observed prior to maximum speed of clot growth; maximum rate of thrombus generation (MRTG): this is the maximum velocity of clot growth observed (dynes/cm 2 /sec.); and total thrombus generation (TTG, dynes/cm 2 ), the final viscoelastic resistance observed after clot formation. Lastly, the contribution of platelets and plasma to clot strength was determined by the difference in TTG values between platelet-intact and platelet-inhibited samples, similar to previously described methodology [8] .
Protocol for administration of C. atrox venom without or with preexposure to CO to rabbits, followed by thromboelastographic assessment of coagulation. As previously described [7] , rabbits were briefly restrained and had one ear closely clipped and cleaned with a 70% isopropyl alcohol pad. A 22-G plastic catheter was placed in the distal third of the central ear artery and another similar catheter placed in the marginal ear vein. The animals were sedated intravenously with 1 mg/kg midazolam (Akorn Inc., Lake Forest, IL, USA), with supplemental doses of 0.5-1 mg/kg/hr provided during experimentation to maintain sedation. One forepaw was subsequently closely clipped, with a pulse oximeter probe placed to monitor heart rate (HR, beats/ min.) and % arterial oxygenation (SpO 2 ) with a Radical 7â monitor using a Rainbowâ R1 25L probe capable of detecting % carboxyhemoglobin that was manufactured and provided by Masimo Corporation (Irvine, CA, USA). Heart rate (HR) and SpO 2 were recorded at baseline and every 15 min. thereafter until the end of the experiment. A baseline 1-ml arterial whole-blood sample was collected and within 3 min. was divided into platelet-intact and platelet-inhibited samples in two different thromboelastographic cups with analyses commenced.
Exposure of C. atrox venom to vehicle or CO was performed as subsequently described. Venom equal to 400 lg/kg for each individual rabbit was suspended in 1 ml of PBS; then, a 1% addition of either DMSO or CORM-2 (final concentration 1000 lM) was mixed into the venom which was then incubated at 39°C in a water bath for 5 min. The concentration of venom administered was less than what was previously used [7] , so as to still have a significant effect on coagulation, but less likely to severely compromise coagulation as was seen at a dose of 500 lg/kg. The concentration of CORM-2 was based on the highest concentration used in vitro and in living systems without adverse effects [12, 13] . The venom mixture was then diluted to a final volume of 3 ml with PlasmaLyte solution (pH 7.4, Baxter International, Deerfield, IL, USA) and then administered intravenously over 3 min. to the rabbit. One hour after injection, a 1-ml arterial wholeblood sample was collected and analysed in a fashion identical to the baseline sample. Thereafter, the rabbits were killed with intravenous administration of 1 ml of pentobarbital/phenytoin (390/50 mg/ml; Henry Schein, Dublin, OH, USA).
Statistical analyses. Data are presented as mean AE S.D. Experimental groups were represented by n = 7-8 different individuals, as this provides a statistical power >0.8 with p ≤ 0.05 using this thromboelastographic methodology [7] . A commercially available statistical program was used for two-way repeated measures analyses of variance (ANOVA), followed by Holm-Sidak post hoc analyses as appropriate (SigmaStat 3.1, Systat Software, Inc., San Jose, CA, USA). Graphics depicting coagulation kinetic data were generated with a commercially available program (OrigenPro 2017, OrigenLab Corporation, Northampton, MA, USA). P < 0.05 was considered significant.
Results

General results.
Eight rabbits completed experiments wherein venom not exposed to CO was administered, but only seven rabbits administered venom exposed to CO were able to complete the protocol secondary to loss of vascular access and inability to collect blood samples. Both groups of rabbits were 2.2 AE 0.1 kg. Of interest, there was no detectable carboxyhemoglobin in either group of rabbits throughout experimentation. There was no significant change in HR or SpO 2 over time nor were there any differences between the two groups. Lastly, the average values for HR were 223-231 beats/min., and the average values for SpO 2 were 93-96%.
Effects of CO exposure on fibrinogenolytic activity of C. atrox venom in vivo. Thromboelastographic data derived from platelet-intact samples are depicted in fig. 1 and platelet-inhibited data are displayed in fig. 2 . Platelet activity-intact samples -Following envenomation, in the group administered CO-na€ ıve venom, there was a significant increase in TMRTG values (53%), decrease in MRTG values (32%) and decrease in TTG values (30%) after 1 hr. In contrast, in the group administered COexposed venom, there was no significant change in TMRTG or MRTG values 1 hr after envenomation. However, there was a significant decrease in TTG values (14%) 1 hr after envenomation in this second group of rabbits. Lastly, the group administered CO-exposed venom had significantly smaller TMRTG values, greater MRTG values and TTG values compared to rabbits administered CO-na€ ıve venom. Plateletinhibited samples -Following envenomation, in the group administered CO-na€ ıve venom, there was a significant increase in TMRTG values (90%), decrease in MRTG values (36%), but no significant decrease in TTG values after 1 hr. In contrast, in the group administered CO-exposed venom, there was no significant change in TMRTG or MRTG values 1 hr after envenomation. However, there was a significant increase in TTG values (14%) 1 hr after envenomation in the second group of rabbits. Lastly, the group administered CO-exposed venom had significantly smaller TMRTG values, greater MRTG values, but not different TTG values compared to rabbits administered CO-na€ ıve venom.
With regard to the contribution of platelets or plasmatic proteins to clot strength, in the group administered CO-na€ ıve venom, the baseline contribution of platelets was 89.3 AE 3.1% and the plasma protein contribution was 10.7 AE 3.1%. An hour after envenomation, there was a significant decrease in the platelet contribution to 84.9 AE 2.4% and concordant significant increase in the plasma protein contribution to 15.1 AE 2.4%. In the case of animals administered CO-exposed venom, the platelet contribution was 90.1 AE 2.4% and the plasma protein contribution was 9.9%AE2.4% prior to envenomation. Following venom administration in the second group, there was a significant decrease in the platelet contribution to 87.1 AE 3.8% and increase in plasma protein contribution of 12.9 AE 3.8%. Lastly, there were no significant differences in platelet or plasma protein contributions to clot strength between the two groups of rabbits.
Discussion
The primary finding of the present study was that pre-treatment of C. atrox venom with CO in vitro either eliminated or diminished its fibrinogenolytic activity in a sedated rabbit model. Specifically, the venom-mediated effects on TMRTG and MRTG were abrogated in whole blood, with or without platelet inhibition; further, in whole blood, the venommediated loss of clot strength was also diminished by CO pre-treatment. Of interest, this venom does not affect platelet glycoprotein IIb/IIIa [14] , and platelet binding to fibrin polymers via glycoprotein IIb/IIIa is the basis for assessment of platelet-mediated effects in thromboelastography [9, 15] . Thus, venom-mediated coagulation kinetic changes in whole blood with uninhibited platelet activity is likely secondary to damage to fibrinogen with consequent formation of fibrin polymers with poor organization and perhaps diminished binding sites for glycoprotein IIb/IIIa. In further support of the concept that C. atrox venom diminishes the binding characteristics of fibrin polymers with platelets, the contribution of platelets to clot strength diminished in both groups to a similar extent with concordant increase in the contribution of plasma proteins to clot strength. However, in absolute TTG values, there was no significant change in clot strength in platelet-inhibited samples obtained from rabbits administered unmodified venom, and an increase in TTG in similar samples obtained from the other group of rabbits was observed ( fig. 2) . When considered as a whole, these data suggest that CO-mediated inhibition of C. atrox venom protects against absolute loss of fibrinogen function when protein-dependent clot formation is considered; however, protection against venom-mediated degradation of fibrin polymer-platelet binding sites and coagulation kinetics may not be afforded by exposure of venom to CO.
Exposure of rabbit whole blood and plasma to C. atrox venom results in a loss of clot strength in vitro as well as Fig. 1 . Effects of venom exposure to CO prior to administration to rabbits; whole-blood coagulation kinetics. Data are presented as mean AE S.D. Black bars represent data obtained from rabbits administered venom without CO exposure; white bars represent data obtained from rabbits administered venom with CO exposure. TMRTG, time to maximum rate of thrombus generation (min); MRTG, maximum rate of thrombus generation (dynes/cm 2 /sec.); TTG, total thrombus generation (dynes/cm 2 ). *P < 0.03 versus baseline; †p < 0.03 versus samples obtained from rabbits administered venom without CO exposure.
increasing TMRTG and decreasing MRTG [7] . In contrast, while TMRTG was significantly increased and MRTG significantly decreased an hour after venom administration, TTG values did not change in animals exposed to CO-na€ ıve venom ( fig. 2) . While a lack of change in TTG could be secondary to the dose of venom not being sufficient to achieve a loss of strength, other possibilities include the clearance of fibrin split products (FSP) from the circulation that were formed during the initial catalysis of fibrinogen. FSP significantly interfere with fibrin polymerization [16] [17] [18] , and FSP cannot be removed from whole blood or plasma in vitro, perhaps explaining the difference between the results of the present in vivo investigation and our recent in vitro study with rabbits [7] . What is more difficult to explain is the significant increase in TTG in platelet-inhibited whole-blood samples obtained from rabbits administered CO-exposed venom ( fig. 2) . Given that venom contains several compounds/enzymes that would induce systemic inflammation, it may be possible that while CO inhibits fibrinogenolytic enzymes, other mediators may be unaffected and induce rapid acute-phase reactant release (such as fibrinogen). When considered together, the unanticipated lack of decrease in clot strength (CO-na€ ıve venom) or increase in clot strength (CO-exposed venom) cannot be easily explained with the design of the present study and serve as a rationale to pursue molecular explanations in future in vitro investigations.
One matter not addressed by the present investigation is the role played by changes in red blood cell morphology in clot formation, specifically the contracted state known as eryptosis. This change in shape, contractile in nature, has recently been described with scanning electron microscopy in whole blood after exposure to the fibrinogenolytic venom of Bitis arietans, likely secondary to exposure to cytotoxic, haemorrhagic metalloproteases [19] . Eryptosis has been linked to inflammatory states that may have hypercoagulability as a prominent feature; thus, it is posited that this change in shape, perhaps during clot formation, may enhance clot strength [20, 21] . The concept is that fibrin polymers attached to RBC undergoing eryptosis may have increased tension exerted by the RBC, analogous to platelet attachment and contraction. While this may be the case, this cannot be measured with thromboelastography in scenarios involving fibrinogenolytic venoms such as those obtained with C. atrox and as demonstrated with B. arietans [19] , as the enzymatic digestion of fibrinogen degrades clot strength. However, in the setting of envenomation by vipers with venom containing thrombin-like activity [4, 5] , there could be a role for haemorrhagic metalloprotease-mediated eryptosis in enhancing whole-blood clot strength. If the eryptosis occurs during or shortly after clot formation, then it is possible RBC morphological changes may affect clot strength. However, if eryptosis occurs before clot formation, then there would be no further tension placed on the fibrin mesh than would be expected with any formed blood cell not actively changing shape. While beyond the scope of the present manuscript, the matter is worthy of future investigation.
In conclusion, the present investigation demonstrates for the first time in vivo that CO-mediated inhibition of C. atrox venom in vitro markedly diminishes its fibrinogenolytic properties in whole blood in the rabbit. These data serve as the rationale for future studies to determine whether rabbits injected with such venom subcutaneously or intramuscularly Fig. 2 . Effects of venom exposure to CO prior to administration to rabbits; whole-blood coagulation kinetics with platelet inhibition. Data are presented as mean AE S.D. Black bars represent data obtained from rabbits administered venom without CO exposure; white bars represent data obtained from rabbits administered venom with CO exposure. All samples had platelet inhibition in whole blood with cytochalasin D prior to analyses. TMRTG, time to maximum rate of thrombus generation (min); MRTG, maximum rate of thrombus generation (dynes/cm 2 / sec); TTG, total thrombus generation (dynes/cm 2 ). *P < 0.02 versus baseline; †P < 0.02 versus samples obtained from rabbits administered venom without CO exposure.
can have consequent coagulopathy abrogated by injection of carbon monoxide-releasing molecules into the 'bite site'.
